Kenvue Inc. (NYSE:KVUE) Receives Average Recommendation of “Hold” from Analysts

Shares of Kenvue Inc. (NYSE:KVUE) have been given an average rating of “Hold” by the fourteen research firms that are presently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, eight have given a hold rating and five have issued a buy rating on the company. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is $23.00.

A number of research firms recently commented on KVUE. Piper Sandler raised shares of Kenvue from a “neutral” rating to an “overweight” rating and increased their target price for the company from $21.00 to $26.00 in a research report on Monday, January 6th. Citigroup dropped their price objective on Kenvue from $25.00 to $21.00 and set a “neutral” rating on the stock in a report on Wednesday, January 15th. Deutsche Bank Aktiengesellschaft downgraded Kenvue from a “buy” rating to a “hold” rating and reduced their target price for the company from $25.00 to $24.00 in a report on Thursday, December 12th. Barclays dropped their price target on Kenvue from $23.00 to $21.00 and set an “equal weight” rating on the stock in a research note on Friday, January 17th. Finally, Canaccord Genuity Group reduced their price objective on Kenvue from $27.00 to $24.00 and set a “buy” rating for the company in a research note on Friday, February 7th.

Hedge Funds Weigh In On Kenvue

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Huber Capital Management LLC raised its position in Kenvue by 15.6% during the 4th quarter. Huber Capital Management LLC now owns 169,300 shares of the company’s stock worth $3,615,000 after buying an additional 22,900 shares during the last quarter. Allen Wealth Management LLC boosted its holdings in shares of Kenvue by 7.8% in the fourth quarter. Allen Wealth Management LLC now owns 82,559 shares of the company’s stock valued at $1,763,000 after acquiring an additional 6,001 shares in the last quarter. Westpac Banking Corp increased its stake in shares of Kenvue by 68.5% during the fourth quarter. Westpac Banking Corp now owns 325,615 shares of the company’s stock worth $6,952,000 after acquiring an additional 132,327 shares during the period. Bryce Point Capital LLC purchased a new position in Kenvue during the fourth quarter worth about $469,000. Finally, Huntington National Bank lifted its position in Kenvue by 44.4% in the fourth quarter. Huntington National Bank now owns 6,007 shares of the company’s stock valued at $128,000 after purchasing an additional 1,846 shares during the period. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

Kenvue Price Performance

Shares of NYSE KVUE opened at $20.96 on Thursday. The stock’s 50-day simple moving average is $21.41 and its 200-day simple moving average is $22.03. The firm has a market capitalization of $40.19 billion, a PE ratio of 39.55, a price-to-earnings-growth ratio of 2.16 and a beta of 1.45. Kenvue has a fifty-two week low of $17.67 and a fifty-two week high of $24.46. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.69 and a current ratio of 1.00.

Kenvue (NYSE:KVUE) last announced its quarterly earnings results on Thursday, February 6th. The company reported $0.26 EPS for the quarter, meeting the consensus estimate of $0.26. Kenvue had a net margin of 6.66% and a return on equity of 20.97%. As a group, equities research analysts forecast that Kenvue will post 1.05 EPS for the current fiscal year.

Kenvue Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, February 26th. Stockholders of record on Wednesday, February 12th will be paid a dividend of $0.205 per share. This represents a $0.82 annualized dividend and a dividend yield of 3.91%. The ex-dividend date is Wednesday, February 12th. Kenvue’s dividend payout ratio (DPR) is presently 154.72%.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.